Charles River Laboratories (CRL) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Charles River Laboratories · Health Care · ref. ETF XLV · 52 calls · price $296.41
What the company does: Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
📈 Charles River Laboratories (CRL) stock price
$296.41+81.6% over range
Aug 28, 25low $145.57 · high $298.58Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
75% recommend buying · 8 analysts
📊 JPI status : Charles River Laboratories has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Buy” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 CRL price target & analyst consensus — price $296
The price target · all analysts combined (8 targets)
Highest target · 1 firm of 8$310+4.6%
Median target · of 8 targets$291-1.8%
Lowest target · 1 firm of 8$219-26.1%
Current price$296.41
Where these 8 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
450%
$300 ↔ $310
Below
450%
$219 ↔ $282
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $300 (+1.2 %), call made on August 8, 2026, maturing on August 8, 2027 (20 d ago).
The 4 reliable analysts
$300+1.2 %
The 4 other firms
$251-15 %
How to read it: the 4 reliable firms are not filtered by optimism — 3 aim above the price, 1 below, hence their $300 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 8 ratings (last 6 months)
Strong Buy00%
Buy675%
Hold225%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 CRL price target all
All 52 calls, one by one, with our verdict on each firm.
→ See all 52 targets, analyst by analyst💡 The best analysts on CRL most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in CRL? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Charles River Laboratories? The JPI assistant answers using our backtest data.
📈 Charles River Laboratories fundamentals: valuation, margins & growth › open the full page
P/E —Net margin -6.0 %Revenue growth -2.7 %Not (yet) profitable
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 12 %
2023
Rev +4%Profit −2%
2024
Rev −2%Profit −98%
2025
Rev −1%Profit −1502%
🔎 Detailed analyses
✅ Historical analyst reliability on CRL
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| SunTrust Robinson Humphrey | 100% | +86.4% | 6 |
| Sterne Agee | 100% | +30.5% | 3 |
| William Blair ↗ | 100% | +19.3% | 2 |
| Redburn Atlantic | 100% | +13.3% | 2 |
| Guggenheim ↗ | 100% | +6.1% | 2 |
| Jefferies ↗ | 86% | +29.8% | 14 |
| B of A Securities ↗ | 80% | +33.0% | 5 |
| Citigroup ↗ | 78% | +43.0% | 9 |
| Deutsche Bank ↗ | 75% | +42.6% | 4 |
| Argus Research ↗ | 75% | +22.6% | 4 |
See the other 13 firms
| Barclays ↗ | 0% | -11.9% | 2 |
| UBS ↗ | 29% | -5.3% | 7 |
| Raymond James ↗ | 33% | -8.1% | 3 |
| JP Morgan ↗ | 38% | +7.0% | 8 |
| Goldman Sachs ↗ | 40% | +4.4% | 5 |
| Truist Securities ↗ | 50% | -16.1% | 2 |
| Credit Suisse | 50% | +1.5% | 4 |
| Baird ↗ | 50% | +3.5% | 10 |
| RBC Capital ↗ | 50% | +4.8% | 2 |
| Keybanc ↗ | 50% | +21.1% | 8 |
| Evercore ISI Group ↗ | 60% | +21.6% | 5 |
| Wells Fargo ↗ | 67% | +24.9% | 9 |
| Morgan Stanley ↗ | 67% | +37.6% | 9 |
📊 What $1,000 invested in Charles River Laboratories would be worth › open the full page
In short — $1,000 invested in Charles River Laboratories 10 years ago would be worth $2,821 today, i.e. +11%/yr on average. Best year: 2020 (+64%), worst: 2022 (-42%). Price performance, excluding dividends.
If I'd invested $1,000 in Charles River Laboratories
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,229 | +23% |
| 3 years ago | $1,041 | +4% |
| 5 years ago | $908 | -9% |
Return by year (Charles River Laboratories)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +14% | $1,137 (+14%) |
| 2025 | +8% | $1,229 (+23%) |
| 2024 | -22% | $959 (-4%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Charles River Laboratories
Loading news…
📋 All analyst calls on CRL
Filtered on — · ✕ show all
▲ Buy · 🎯$300
Price at call : $282 — upside +6%
Today : $296.41 — upside +1%
🎯 on CRL : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Aug 10, 27
matures : Aug 10, 27
Morgan Stanley ↗
Aug 7, 26
▲ Overweight · 🎯$300
Price at call : $277 — upside +8%
Today : $296.41 — upside +1%
🎯 on CRL : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
RBC Capital ↗
Aug 6, 26
▲ Outperform · 🎯$282
Price at call : $267.49 — upside +5%
Today : $296.41 — upside -5%
🎯 on CRL : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
Evercore ISI Group ↗
Aug 6, 26
▲ Outperform · 🎯$300
Price at call : $267.49 — upside +12%
Today : $296.41 — upside +1%
🎯 on CRL : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Overweight · 🎯$310
Price at call : $265.51 — upside +17%
Today : $296.41 — upside +5%
🎯 on CRL : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
CLSA
Jul 20, 26
■ Hold neutral · not a buy · 🎯$219
Price at call : $219.7 — gap to target -0%
Today : $296.41 — gap to target -26%
🎯 on CRL : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jul 20, 27
matures : Jul 20, 27
■ Neutral neutral · not a buy · 🎯$230
Price at call : $229.75 — gap to target +0%
Today : $296.41 — gap to target -22%
🎯 on CRL : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
Morgan Stanley ↗
Jul 9, 26
▲ Overweight · 🎯$260
Price at call : $233.41 — upside +11%
Today : $296.41 — upside -12%
🎯 on CRL : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 9, 27
matures : Jul 9, 27
See the other 44 calls, newest to oldest
Morgan Stanley ↗
Jun 17, 26
▲ Overweight · 🎯$220
Price at call : $182.34 — upside +21%
Today : $296.41 — upside -26%
🎯 on CRL : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jun 17, 27
matures : Jun 17, 27
CLSA
May 29, 26
▲ Outperform · 🎯$219
Price at call : $180.71 — upside +21%
Today : $296.41 — upside -26%
🎯 on CRL : no call matured yet · 📊 unranked overall
in progress (365j)
matures : May 29, 27
matures : May 29, 27
▲ Overweight · 🎯$220
Price at call : $168.46 — upside +31%
Today : $296.41 — upside -26%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 8, 27
matures : May 8, 27
Evercore ISI Group ↗
May 8, 26
▲ Outperform · 🎯$220
Price at call : $168.46 — upside +31%
Today : $296.41 — upside -26%
🎯 on CRL : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : May 8, 27
matures : May 8, 27
▲ Overweight · 🎯$210
Price at call : $180.56 — upside +16%
Today : $296.41 — upside -29%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Apr 14, 27
matures : Apr 14, 27
■ Neutral neutral · not a buy · 🎯$160
Price at call : $179.31 — gap to target -11%
Today : $296.41 — gap to target -46%
🎯 on CRL : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
■ Neutral neutral · not a buy · 🎯$175
Price at call : $175.46 — gap to target -0%
Today : $296.41 — gap to target -41%
🎯 on CRL : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Feb 25, 27
matures : Feb 25, 27
▲ Buy · 🎯$235
Price at call : $163.52 — upside +44%
Today : $296.41 — upside -21%
🎯 on CRL : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
■ Neutral neutral · not a buy · 🎯$175
Price at call : $163.52 — gap to target +7%
Today : $296.41 — gap to target -41%
🎯 on CRL : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
▲ Overweight · 🎯$200
Price at call : $168.92 — upside +18%
Today : $296.41 — upside -33%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Evercore ISI Group ↗
Feb 19, 26
▲ Outperform · 🎯$200
Price at call : $164.24 — upside +22%
Today : $296.41 — upside -33%
🎯 on CRL : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
▲ Buy · 🎯$265
Price at call : $218.19 — upside +21%
Today : $296.41 — upside -11%
🎯 on CRL : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 16, 27
matures : Jan 16, 27
Evercore ISI Group ↗
Jan 13, 26
▲ Outperform · 🎯$260
Price at call : $216.39 — upside +20%
Today : $296.41 — upside -12%
🎯 on CRL : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Jan 13, 27
matures : Jan 13, 27
■ Neutral neutral · not a buy · 🎯$200
Price at call : $193.85 — gap to target +3%
Today : $296.41 — gap to target -33%
🎯 on CRL : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Dec 18, 26
matures : Dec 18, 26
▲ Overweight · 🎯$215
Price at call : $195.22 — upside +10%
Today : $296.41 — upside -27%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Dec 15, 26
matures : Dec 15, 26
■ Neutral neutral · not a buy · 🎯$190
Price at call : $195.22 — gap to target -3%
Today : $296.41 — gap to target -36%
🎯 on CRL : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Dec 15, 26
matures : Dec 15, 26
Morgan Stanley ↗
Nov 11, 25
■ Equal-Weight neutral · not a buy · 🎯$185
Price at call : $171.5 — gap to target +8%
Today : $296.41 — gap to target -38%
🎯 on CRL : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Nov 11, 26
matures : Nov 11, 26
▲ Buy · 🎯$197
Price at call : $173.5 — upside +14%
Today : $296.41 — upside -34%
🎯 on CRL : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Nov 10, 26
matures : Nov 10, 26
■ Neutral neutral · not a buy · 🎯$165
Price at call : $168.05 — gap to target -2%
Today : $296.41 — gap to target -44%
🎯 on CRL : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Nov 6, 26
matures : Nov 6, 26
▲ Overweight · 🎯$210
Price at call : $168.05 — upside +25%
Today : $296.41 — upside -29%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Nov 6, 26
matures : Nov 6, 26
▲ Outperform · 🎯$199
Price at call : $170.88 — upside +16%
Today : $296.41 — upside -33%
🎯 on CRL : no call matured yet · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Nov 6, 26
matures : Nov 6, 26
■ Neutral neutral · not a buy · 🎯$174
Price at call : $178.52 — gap to target -3%
Today : $296.41 — gap to target -41%
🎯 on CRL : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Oct 17, 26
matures : Oct 17, 26
William Blair ↗
Oct 6, 25
▲ Outperform
🎯 on CRL : 100% (1 call matured) · 📊 on Health : 63% · +5.2% (27 calls)
in progress (365j)
matures : Oct 6, 26
matures : Oct 6, 26
Evercore ISI Group ↗
Oct 3, 25
▲ Outperform · 🎯$200
Price at call : $174.95 — upside +14%
Today : $296.41 — upside -33%
🎯 on CRL : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Oct 3, 26
matures : Oct 3, 26
▲ Overweight · 🎯$195
Price at call : $175.36 — upside +11%
Today : $296.41 — upside -34%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 2, 26
matures : Oct 2, 26
▲ Buy · 🎯$195
Price at call : $157.38 — upside +24%
Today : $296.41 — upside -34%
🎯 on CRL : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Sep 9, 26
matures : Sep 9, 26
Evercore ISI Group ↗
Aug 8, 25
▲ Outperform · 🎯$190
Price at call : $148.74 — upside +28%
Today : $296.41 — upside -36%
Expected +28% · Actual +86% · Reason (≥ +15%) : ✓ Yes
🎯 on CRL : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
+86.2%
stock +86% · XLV +29%
matured Aug 8, 26
■ Neutral neutral · not a buy · 🎯$160
Price at call : $148.74 — gap to target +8%
Today : $296.41 — gap to target -46%
🎯 on CRL : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Aug 7, 26
matures : Aug 7, 26
■ Equal-Weight neutral · not a buy · 🎯$165
Price at call : $149.78 — gap to target +10%
Today : $296.41 — gap to target -44%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 7, 26
matures : Aug 7, 26
Evercore ISI Group ↗
Jul 9, 25
▲ Outperform · 🎯$180
Price at call : $158.97 — upside +13%
Today : $296.41 — upside -39%
Expected +13% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on CRL : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
+46.9%
stock +47% · XLV +20%
matured Jul 9, 26
▲ Buy · 🎯$200
Price at call : $158.97 — upside +26%
Today : $296.41 — upside -33%
Expected +26% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on CRL : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
+46.9%
stock +47% · XLV +20%
matured Jul 9, 26
Redburn Atlantic
May 23, 25
▲ Buy · 🎯$182
Price at call : $136.73 — upside +33%
Today : $296.41 — upside -39%
Expected +33% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on CRL : 100% (1 call matured) · 📊 unranked overall
+14.6%
stock +15% · XLV +14%
matured May 23, 26
■ Equal-Weight neutral · not a buy · 🎯$155
Price at call : $138.79 — gap to target +12%
Today : $296.41 — gap to target -48%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 8, 26
matures : May 8, 26
■ Neutral neutral · not a buy · 🎯$140
Price at call : $141.36 — gap to target -1%
Today : $296.41 — gap to target -53%
🎯 on CRL : no call matured yet · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : May 8, 26
matures : May 8, 26
■ Equal-Weight neutral · not a buy · 🎯$145
Price at call : $99.75 — gap to target +45%
Today : $296.41 — gap to target -51%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Apr 10, 26
matures : Apr 10, 26
■ Neutral neutral · not a buy · 🎯$155
Price at call : $139.07 — gap to target +11%
Today : $296.41 — gap to target -48%
🎯 on CRL : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Apr 9, 26
matures : Apr 9, 26
Goldman Sachs ↗
Mar 21, 25
■ Neutral neutral · not a buy · 🎯$170
Price at call : $167.28 — gap to target +2%
Today : $296.41 — gap to target -43%
🎯 on CRL : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Mar 21, 26
matures : Mar 21, 26
■ Neutral neutral · not a buy · 🎯$175
Price at call : $164.31 — gap to target +7%
Today : $296.41 — gap to target -41%
🎯 on CRL : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Mar 4, 26
matures : Mar 4, 26
Redburn Atlantic
Mar 3, 25
■ Neutral neutral · not a buy · 🎯$188
Price at call : $163.5 — gap to target +15%
Today : $296.41 — gap to target -37%
🎯 on CRL : 100% (1 call matured) · 📊 unranked overall
in progress (365j)
matures : Mar 3, 26
matures : Mar 3, 26
■ Neutral neutral · not a buy · 🎯$165
Price at call : $163.02 — gap to target +1%
Today : $296.41 — gap to target -44%
🎯 on CRL : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Feb 20, 26
matures : Feb 20, 26
■ Neutral neutral · not a buy · 🎯$173
Price at call : $162.25 — gap to target +7%
Today : $296.41 — gap to target -42%
🎯 on CRL : no call matured yet · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Feb 20, 26
matures : Feb 20, 26
■ Equal-Weight neutral · not a buy · 🎯$160
Price at call : $162.25 — gap to target -1%
Today : $296.41 — gap to target -46%
🎯 on CRL : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 20, 26
matures : Feb 20, 26
William Blair ↗
Jan 22, 25
■ Market Perform neutral · not a buy
🎯 on CRL : 100% (1 call matured) · 📊 on Health : 63% · +5.2% (27 calls)
in progress (365j)
matures : Jan 22, 26
matures : Jan 22, 26
William Blair ↗
Jan 14, 25
▲ Outperform
Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on CRL : 100% (1 call matured) · 📊 on Health : 63% · +5.2% (27 calls)
+28.5%
stock +28% · XLV +12%
matured Jan 14, 26
Frequently asked questions
Should I buy Charles River Laboratories stock?
This isn't buy advice. For Charles River Laboratories, the analyst consensus is "Buy", with an average price target of $291 (-2% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (6 calls tracked on Charles River Laboratories). We show the numbers — you decide.
Is it too late to buy Charles River Laboratories? How high can it go?
The most bullish analyst target on Charles River Laboratories is $310 (+5% above today's price); the average is $291. That's the upside they see. Check how reliable those analysts have actually been on Charles River Laboratories on our site before trusting it.
Is Charles River Laboratories still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 23 analysts have a real record on Charles River Laboratories, the best hitting 100% over 6 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Charles River Laboratories? The case for and against
The arguments for and against, one by one, from the numbers: why invest in CRL (and why hesitate).
What has Charles River Laboratories's past performance been?
Historical returns and a "how much if I had invested" calculator: CRL performance & returns.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX